Table of Content

1 Study Coverage
1.1 PD-1 and PD-L1 Inhibitor Product Introduction
1.2 Market by Type
1.2.1 Global PD-1 and PD-L1 Inhibitor Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 Monoclonal Antibody
1.2.3 Bispecific Antibody
1.3 Market by Application
1.3.1 Global PD-1 and PD-L1 Inhibitor Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Lung Cancer
1.3.3 Stomach Cancer
1.3.4 Breast Cancer
1.3.5 Rectal Cancer
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global PD-1 and PD-L1 Inhibitor Sales Estimates and Forecasts 2018-2034
2.2 Global PD-1 and PD-L1 Inhibitor Revenue by Region
2.2.1 Global PD-1 and PD-L1 Inhibitor Revenue by Region: 2018 VS 2022 VS 2034
2.2.2 Global PD-1 and PD-L1 Inhibitor Revenue by Region (2018-2024)
2.2.3 Global PD-1 and PD-L1 Inhibitor Revenue by Region (2024-2034)
2.2.4 Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Region (2018-2034)
2.3 Global PD-1 and PD-L1 Inhibitor Sales Estimates and Forecasts 2018-2034
2.4 Global PD-1 and PD-L1 Inhibitor Sales by Region
2.4.1 Global PD-1 and PD-L1 Inhibitor Sales by Region: 2018 VS 2022 VS 2034
2.4.2 Global PD-1 and PD-L1 Inhibitor Sales by Region (2018-2024)
2.4.3 Global PD-1 and PD-L1 Inhibitor Sales by Region (2024-2034)
2.4.4 Global PD-1 and PD-L1 Inhibitor Sales Market Share by Region (2018-2034)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global PD-1 and PD-L1 Inhibitor Sales by Manufacturers
3.1.1 Global PD-1 and PD-L1 Inhibitor Sales by Manufacturers (2018-2024)
3.1.2 Global PD-1 and PD-L1 Inhibitor Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of PD-1 and PD-L1 Inhibitor in 2022
3.2 Global PD-1 and PD-L1 Inhibitor Revenue by Manufacturers
3.2.1 Global PD-1 and PD-L1 Inhibitor Revenue by Manufacturers (2018-2024)
3.2.2 Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by PD-1 and PD-L1 Inhibitor Revenue in 2022
3.3 Global Key Players of PD-1 and PD-L1 Inhibitor, Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global PD-1 and PD-L1 Inhibitor Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global PD-1 and PD-L1 Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of PD-1 and PD-L1 Inhibitor, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of PD-1 and PD-L1 Inhibitor, Product Offered and Application
3.8 Global Key Manufacturers of PD-1 and PD-L1 Inhibitor, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global PD-1 and PD-L1 Inhibitor Sales by Type
4.1.1 Global PD-1 and PD-L1 Inhibitor Historical Sales by Type (2018-2024)
4.1.2 Global PD-1 and PD-L1 Inhibitor Forecasted Sales by Type (2024-2034)
4.1.3 Global PD-1 and PD-L1 Inhibitor Sales Market Share by Type (2018-2034)
4.2 Global PD-1 and PD-L1 Inhibitor Revenue by Type
4.2.1 Global PD-1 and PD-L1 Inhibitor Historical Revenue by Type (2018-2024)
4.2.2 Global PD-1 and PD-L1 Inhibitor Forecasted Revenue by Type (2024-2034)
4.2.3 Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Type (2018-2034)
4.3 Global PD-1 and PD-L1 Inhibitor Price by Type
4.3.1 Global PD-1 and PD-L1 Inhibitor Price by Type (2018-2024)
4.3.2 Global PD-1 and PD-L1 Inhibitor Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global PD-1 and PD-L1 Inhibitor Sales by Application
5.1.1 Global PD-1 and PD-L1 Inhibitor Historical Sales by Application (2018-2024)
5.1.2 Global PD-1 and PD-L1 Inhibitor Forecasted Sales by Application (2024-2034)
5.1.3 Global PD-1 and PD-L1 Inhibitor Sales Market Share by Application (2018-2034)
5.2 Global PD-1 and PD-L1 Inhibitor Revenue by Application
5.2.1 Global PD-1 and PD-L1 Inhibitor Historical Revenue by Application (2018-2024)
5.2.2 Global PD-1 and PD-L1 Inhibitor Forecasted Revenue by Application (2024-2034)
5.2.3 Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Application (2018-2034)
5.3 Global PD-1 and PD-L1 Inhibitor Price by Application
5.3.1 Global PD-1 and PD-L1 Inhibitor Price by Application (2018-2024)
5.3.2 Global PD-1 and PD-L1 Inhibitor Price Forecast by Application (2024-2034)
6 US & Canada
6.1 US & Canada PD-1 and PD-L1 Inhibitor Market Size by Type
6.1.1 US & Canada PD-1 and PD-L1 Inhibitor Sales by Type (2018-2034)
6.1.2 US & Canada PD-1 and PD-L1 Inhibitor Revenue by Type (2018-2034)
6.2 US & Canada PD-1 and PD-L1 Inhibitor Market Size by Application
6.2.1 US & Canada PD-1 and PD-L1 Inhibitor Sales by Application (2018-2034)
6.2.2 US & Canada PD-1 and PD-L1 Inhibitor Revenue by Application (2018-2034)
6.3 US & Canada PD-1 and PD-L1 Inhibitor Market Size by Country
6.3.1 US & Canada PD-1 and PD-L1 Inhibitor Revenue by Country: 2018 VS 2022 VS 2034
6.3.2 US & Canada PD-1 and PD-L1 Inhibitor Sales by Country (2018-2034)
6.3.3 US & Canada PD-1 and PD-L1 Inhibitor Revenue by Country (2018-2034)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe PD-1 and PD-L1 Inhibitor Market Size by Type
7.1.1 Europe PD-1 and PD-L1 Inhibitor Sales by Type (2018-2034)
7.1.2 Europe PD-1 and PD-L1 Inhibitor Revenue by Type (2018-2034)
7.2 Europe PD-1 and PD-L1 Inhibitor Market Size by Application
7.2.1 Europe PD-1 and PD-L1 Inhibitor Sales by Application (2018-2034)
7.2.2 Europe PD-1 and PD-L1 Inhibitor Revenue by Application (2018-2034)
7.3 Europe PD-1 and PD-L1 Inhibitor Market Size by Country
7.3.1 Europe PD-1 and PD-L1 Inhibitor Revenue by Country: 2018 VS 2022 VS 2034
7.3.2 Europe PD-1 and PD-L1 Inhibitor Sales by Country (2018-2034)
7.3.3 Europe PD-1 and PD-L1 Inhibitor Revenue by Country (2018-2034)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China PD-1 and PD-L1 Inhibitor Market Size
8.1.1 China PD-1 and PD-L1 Inhibitor Sales (2018-2034)
8.1.2 China PD-1 and PD-L1 Inhibitor Revenue (2018-2034)
8.2 China PD-1 and PD-L1 Inhibitor Market Size by Application
8.2.1 China PD-1 and PD-L1 Inhibitor Sales by Application (2018-2034)
8.2.2 China PD-1 and PD-L1 Inhibitor Revenue by Application (2018-2034)
9 Asia (excluding China)
9.1 Asia PD-1 and PD-L1 Inhibitor Market Size by Type
9.1.1 Asia PD-1 and PD-L1 Inhibitor Sales by Type (2018-2034)
9.1.2 Asia PD-1 and PD-L1 Inhibitor Revenue by Type (2018-2034)
9.2 Asia PD-1 and PD-L1 Inhibitor Market Size by Application
9.2.1 Asia PD-1 and PD-L1 Inhibitor Sales by Application (2018-2034)
9.2.2 Asia PD-1 and PD-L1 Inhibitor Revenue by Application (2018-2034)
9.3 Asia PD-1 and PD-L1 Inhibitor Sales by Region
9.3.1 Asia PD-1 and PD-L1 Inhibitor Revenue by Region: 2018 VS 2022 VS 2034
9.3.2 Asia PD-1 and PD-L1 Inhibitor Revenue by Region (2018-2034)
9.3.3 Asia PD-1 and PD-L1 Inhibitor Sales by Region (2018-2034)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America PD-1 and PD-L1 Inhibitor Market Size by Type
10.1.1 Middle East, Africa and Latin America PD-1 and PD-L1 Inhibitor Sales by Type (2018-2034)
10.1.2 Middle East, Africa and Latin America PD-1 and PD-L1 Inhibitor Revenue by Type (2018-2034)
10.2 Middle East, Africa and Latin America PD-1 and PD-L1 Inhibitor Market Size by Application
10.2.1 Middle East, Africa and Latin America PD-1 and PD-L1 Inhibitor Sales by Application (2018-2034)
10.2.2 Middle East, Africa and Latin America PD-1 and PD-L1 Inhibitor Revenue by Application (2018-2034)
10.3 Middle East, Africa and Latin America PD-1 and PD-L1 Inhibitor Sales by Country
10.3.1 Middle East, Africa and Latin America PD-1 and PD-L1 Inhibitor Revenue by Country: 2018 VS 2022 VS 2034
10.3.2 Middle East, Africa and Latin America PD-1 and PD-L1 Inhibitor Revenue by Country (2018-2034)
10.3.3 Middle East, Africa and Latin America PD-1 and PD-L1 Inhibitor Sales by Country (2018-2034)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Merck
11.1.1 Merck Company Information
11.1.2 Merck Overview
11.1.3 Merck PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 Merck PD-1 and PD-L1 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Merck Recent Developments
11.2 Bristol-Myers Squibb
11.2.1 Bristol-Myers Squibb Company Information
11.2.2 Bristol-Myers Squibb Overview
11.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Bristol-Myers Squibb Recent Developments
11.3 Pfizer
11.3.1 Pfizer Company Information
11.3.2 Pfizer Overview
11.3.3 Pfizer PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 Pfizer PD-1 and PD-L1 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Pfizer Recent Developments
11.4 Sanofi
11.4.1 Sanofi Company Information
11.4.2 Sanofi Overview
11.4.3 Sanofi PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 Sanofi PD-1 and PD-L1 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Sanofi Recent Developments
11.5 Regeneron Pharmaceuticals
11.5.1 Regeneron Pharmaceuticals Company Information
11.5.2 Regeneron Pharmaceuticals Overview
11.5.3 Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Regeneron Pharmaceuticals Recent Developments
11.6 Roche
11.6.1 Roche Company Information
11.6.2 Roche Overview
11.6.3 Roche PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2018-2024)
11.6.4 Roche PD-1 and PD-L1 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Roche Recent Developments
11.7 AstraZeneca
11.7.1 AstraZeneca Company Information
11.7.2 AstraZeneca Overview
11.7.3 AstraZeneca PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2018-2024)
11.7.4 AstraZeneca PD-1 and PD-L1 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 AstraZeneca Recent Developments
11.8 Bristol Myers Squibb
11.8.1 Bristol Myers Squibb Company Information
11.8.2 Bristol Myers Squibb Overview
11.8.3 Bristol Myers Squibb PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2018-2024)
11.8.4 Bristol Myers Squibb PD-1 and PD-L1 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Bristol Myers Squibb Recent Developments
11.9 Hengrui Medicine
11.9.1 Hengrui Medicine Company Information
11.9.2 Hengrui Medicine Overview
11.9.3 Hengrui Medicine PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2018-2024)
11.9.4 Hengrui Medicine PD-1 and PD-L1 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Hengrui Medicine Recent Developments
11.10 Beigene
11.10.1 Beigene Company Information
11.10.2 Beigene Overview
11.10.3 Beigene PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2018-2024)
11.10.4 Beigene PD-1 and PD-L1 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Beigene Recent Developments
11.11 Innovent Biologics
11.11.1 Innovent Biologics Company Information
11.11.2 Innovent Biologics Overview
11.11.3 Innovent Biologics PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2018-2024)
11.11.4 Innovent Biologics PD-1 and PD-L1 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Innovent Biologics Recent Developments
11.12 Junshi Biosciences
11.12.1 Junshi Biosciences Company Information
11.12.2 Junshi Biosciences Overview
11.12.3 Junshi Biosciences PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2018-2024)
11.12.4 Junshi Biosciences PD-1 and PD-L1 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Junshi Biosciences Recent Developments
11.13 Akeso
11.13.1 Akeso Company Information
11.13.2 Akeso Overview
11.13.3 Akeso PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2018-2024)
11.13.4 Akeso PD-1 and PD-L1 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Akeso Recent Developments
11.14 Alphamab Oncology
11.14.1 Alphamab Oncology Company Information
11.14.2 Alphamab Oncology Overview
11.14.3 Alphamab Oncology PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2018-2024)
11.14.4 Alphamab Oncology PD-1 and PD-L1 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Alphamab Oncology Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 PD-1 and PD-L1 Inhibitor Industry Chain Analysis
12.2 PD-1 and PD-L1 Inhibitor Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 PD-1 and PD-L1 Inhibitor Production Mode & Process
12.4 PD-1 and PD-L1 Inhibitor Sales and Marketing
12.4.1 PD-1 and PD-L1 Inhibitor Sales Channels
12.4.2 PD-1 and PD-L1 Inhibitor Distributors
12.5 PD-1 and PD-L1 Inhibitor Customers
13 Market Dynamics
13.1 PD-1 and PD-L1 Inhibitor Industry Trends
13.2 PD-1 and PD-L1 Inhibitor Market Drivers
13.3 PD-1 and PD-L1 Inhibitor Market Challenges
13.4 PD-1 and PD-L1 Inhibitor Market Restraints
14 Key Findings in The Global PD-1 and PD-L1 Inhibitor Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global PD-1 and PD-L1 Inhibitor Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Monoclonal Antibody
Table 3. Major Manufacturers of Bispecific Antibody
Table 4. Global PD-1 and PD-L1 Inhibitor Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 5. Global PD-1 and PD-L1 Inhibitor Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 6. Global PD-1 and PD-L1 Inhibitor Revenue by Region (2018-2024) & (US$ Million)
Table 7. Global PD-1 and PD-L1 Inhibitor Revenue by Region (2024-2034) & (US$ Million)
Table 8. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Region (2018-2024)
Table 9. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Region (2024-2034)
Table 10. Global PD-1 and PD-L1 Inhibitor Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 11. Global PD-1 and PD-L1 Inhibitor Sales by Region (2018-2024) & (K Units)
Table 12. Global PD-1 and PD-L1 Inhibitor Sales by Region (2024-2034) & (K Units)
Table 13. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Region (2018-2024)
Table 14. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Region (2024-2034)
Table 15. Global PD-1 and PD-L1 Inhibitor Sales by Manufacturers (2018-2024) & (K Units)
Table 16. Global PD-1 and PD-L1 Inhibitor Sales Share by Manufacturers (2018-2024)
Table 17. Global PD-1 and PD-L1 Inhibitor Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 18. Global PD-1 and PD-L1 Inhibitor Revenue Share by Manufacturers (2018-2024)
Table 19. Global Key Players of PD-1 and PD-L1 Inhibitor, Industry Ranking, 2021 VS 2022 VS 2024
Table 20. PD-1 and PD-L1 Inhibitor Price by Manufacturers 2018-2024 (US$/Unit)
Table 21. Global PD-1 and PD-L1 Inhibitor Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global PD-1 and PD-L1 Inhibitor by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PD-1 and PD-L1 Inhibitor as of 2022)
Table 23. Global Key Manufacturers of PD-1 and PD-L1 Inhibitor, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of PD-1 and PD-L1 Inhibitor, Product Offered and Application
Table 25. Global Key Manufacturers of PD-1 and PD-L1 Inhibitor, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global PD-1 and PD-L1 Inhibitor Sales by Type (2018-2024) & (K Units)
Table 28. Global PD-1 and PD-L1 Inhibitor Sales by Type (2024-2034) & (K Units)
Table 29. Global PD-1 and PD-L1 Inhibitor Sales Share by Type (2018-2024)
Table 30. Global PD-1 and PD-L1 Inhibitor Sales Share by Type (2024-2034)
Table 31. Global PD-1 and PD-L1 Inhibitor Revenue by Type (2018-2024) & (US$ Million)
Table 32. Global PD-1 and PD-L1 Inhibitor Revenue by Type (2024-2034) & (US$ Million)
Table 33. Global PD-1 and PD-L1 Inhibitor Revenue Share by Type (2018-2024)
Table 34. Global PD-1 and PD-L1 Inhibitor Revenue Share by Type (2024-2034)
Table 35. PD-1 and PD-L1 Inhibitor Price by Type (2018-2024) & (US$/Unit)
Table 36. Global PD-1 and PD-L1 Inhibitor Price Forecast by Type (2024-2034) & (US$/Unit)
Table 37. Global PD-1 and PD-L1 Inhibitor Sales by Application (2018-2024) & (K Units)
Table 38. Global PD-1 and PD-L1 Inhibitor Sales by Application (2024-2034) & (K Units)
Table 39. Global PD-1 and PD-L1 Inhibitor Sales Share by Application (2018-2024)
Table 40. Global PD-1 and PD-L1 Inhibitor Sales Share by Application (2024-2034)
Table 41. Global PD-1 and PD-L1 Inhibitor Revenue by Application (2018-2024) & (US$ Million)
Table 42. Global PD-1 and PD-L1 Inhibitor Revenue by Application (2024-2034) & (US$ Million)
Table 43. Global PD-1 and PD-L1 Inhibitor Revenue Share by Application (2018-2024)
Table 44. Global PD-1 and PD-L1 Inhibitor Revenue Share by Application (2024-2034)
Table 45. PD-1 and PD-L1 Inhibitor Price by Application (2018-2024) & (US$/Unit)
Table 46. Global PD-1 and PD-L1 Inhibitor Price Forecast by Application (2024-2034) & (US$/Unit)
Table 47. US & Canada PD-1 and PD-L1 Inhibitor Sales by Type (2018-2024) & (K Units)
Table 48. US & Canada PD-1 and PD-L1 Inhibitor Sales by Type (2024-2034) & (K Units)
Table 49. US & Canada PD-1 and PD-L1 Inhibitor Revenue by Type (2018-2024) & (US$ Million)
Table 50. US & Canada PD-1 and PD-L1 Inhibitor Revenue by Type (2024-2034) & (US$ Million)
Table 51. US & Canada PD-1 and PD-L1 Inhibitor Sales by Application (2018-2024) & (K Units)
Table 52. US & Canada PD-1 and PD-L1 Inhibitor Sales by Application (2024-2034) & (K Units)
Table 53. US & Canada PD-1 and PD-L1 Inhibitor Revenue by Application (2018-2024) & (US$ Million)
Table 54. US & Canada PD-1 and PD-L1 Inhibitor Revenue by Application (2024-2034) & (US$ Million)
Table 55. US & Canada PD-1 and PD-L1 Inhibitor Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 56. US & Canada PD-1 and PD-L1 Inhibitor Revenue by Country (2018-2024) & (US$ Million)
Table 57. US & Canada PD-1 and PD-L1 Inhibitor Revenue by Country (2024-2034) & (US$ Million)
Table 58. US & Canada PD-1 and PD-L1 Inhibitor Sales by Country (2018-2024) & (K Units)
Table 59. US & Canada PD-1 and PD-L1 Inhibitor Sales by Country (2024-2034) & (K Units)
Table 60. Europe PD-1 and PD-L1 Inhibitor Sales by Type (2018-2024) & (K Units)
Table 61. Europe PD-1 and PD-L1 Inhibitor Sales by Type (2024-2034) & (K Units)
Table 62. Europe PD-1 and PD-L1 Inhibitor Revenue by Type (2018-2024) & (US$ Million)
Table 63. Europe PD-1 and PD-L1 Inhibitor Revenue by Type (2024-2034) & (US$ Million)
Table 64. Europe PD-1 and PD-L1 Inhibitor Sales by Application (2018-2024) & (K Units)
Table 65. Europe PD-1 and PD-L1 Inhibitor Sales by Application (2024-2034) & (K Units)
Table 66. Europe PD-1 and PD-L1 Inhibitor Revenue by Application (2018-2024) & (US$ Million)
Table 67. Europe PD-1 and PD-L1 Inhibitor Revenue by Application (2024-2034) & (US$ Million)
Table 68. Europe PD-1 and PD-L1 Inhibitor Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 69. Europe PD-1 and PD-L1 Inhibitor Revenue by Country (2018-2024) & (US$ Million)
Table 70. Europe PD-1 and PD-L1 Inhibitor Revenue by Country (2024-2034) & (US$ Million)
Table 71. Europe PD-1 and PD-L1 Inhibitor Sales by Country (2018-2024) & (K Units)
Table 72. Europe PD-1 and PD-L1 Inhibitor Sales by Country (2024-2034) & (K Units)
Table 73. China PD-1 and PD-L1 Inhibitor Sales by Type (2018-2024) & (K Units)
Table 74. China PD-1 and PD-L1 Inhibitor Sales by Type (2024-2034) & (K Units)
Table 75. China PD-1 and PD-L1 Inhibitor Revenue by Type (2018-2024) & (US$ Million)
Table 76. China PD-1 and PD-L1 Inhibitor Revenue by Type (2024-2034) & (US$ Million)
Table 77. China PD-1 and PD-L1 Inhibitor Sales by Application (2018-2024) & (K Units)
Table 78. China PD-1 and PD-L1 Inhibitor Sales by Application (2024-2034) & (K Units)
Table 79. China PD-1 and PD-L1 Inhibitor Revenue by Application (2018-2024) & (US$ Million)
Table 80. China PD-1 and PD-L1 Inhibitor Revenue by Application (2024-2034) & (US$ Million)
Table 81. Asia PD-1 and PD-L1 Inhibitor Sales by Type (2018-2024) & (K Units)
Table 82. Asia PD-1 and PD-L1 Inhibitor Sales by Type (2024-2034) & (K Units)
Table 83. Asia PD-1 and PD-L1 Inhibitor Revenue by Type (2018-2024) & (US$ Million)
Table 84. Asia PD-1 and PD-L1 Inhibitor Revenue by Type (2024-2034) & (US$ Million)
Table 85. Asia PD-1 and PD-L1 Inhibitor Sales by Application (2018-2024) & (K Units)
Table 86. Asia PD-1 and PD-L1 Inhibitor Sales by Application (2024-2034) & (K Units)
Table 87. Asia PD-1 and PD-L1 Inhibitor Revenue by Application (2018-2024) & (US$ Million)
Table 88. Asia PD-1 and PD-L1 Inhibitor Revenue by Application (2024-2034) & (US$ Million)
Table 89. Asia PD-1 and PD-L1 Inhibitor Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 90. Asia PD-1 and PD-L1 Inhibitor Revenue by Region (2018-2024) & (US$ Million)
Table 91. Asia PD-1 and PD-L1 Inhibitor Revenue by Region (2024-2034) & (US$ Million)
Table 92. Asia PD-1 and PD-L1 Inhibitor Sales by Region (2018-2024) & (K Units)
Table 93. Asia PD-1 and PD-L1 Inhibitor Sales by Region (2024-2034) & (K Units)
Table 94. Middle East, Africa and Latin America PD-1 and PD-L1 Inhibitor Sales by Type (2018-2024) & (K Units)
Table 95. Middle East, Africa and Latin America PD-1 and PD-L1 Inhibitor Sales by Type (2024-2034) & (K Units)
Table 96. Middle East, Africa and Latin America PD-1 and PD-L1 Inhibitor Revenue by Type (2018-2024) & (US$ Million)
Table 97. Middle East, Africa and Latin America PD-1 and PD-L1 Inhibitor Revenue by Type (2024-2034) & (US$ Million)
Table 98. Middle East, Africa and Latin America PD-1 and PD-L1 Inhibitor Sales by Application (2018-2024) & (K Units)
Table 99. Middle East, Africa and Latin America PD-1 and PD-L1 Inhibitor Sales by Application (2024-2034) & (K Units)
Table 100. Middle East, Africa and Latin America PD-1 and PD-L1 Inhibitor Revenue by Application (2018-2024) & (US$ Million)
Table 101. Middle East, Africa and Latin America PD-1 and PD-L1 Inhibitor Revenue by Application (2024-2034) & (US$ Million)
Table 102. Middle East, Africa and Latin America PD-1 and PD-L1 Inhibitor Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 103. Middle East, Africa and Latin America PD-1 and PD-L1 Inhibitor Revenue by Country (2018-2024) & (US$ Million)
Table 104. Middle East, Africa and Latin America PD-1 and PD-L1 Inhibitor Revenue by Country (2024-2034) & (US$ Million)
Table 105. Middle East, Africa and Latin America PD-1 and PD-L1 Inhibitor Sales by Country (2018-2024) & (K Units)
Table 106. Middle East, Africa and Latin America PD-1 and PD-L1 Inhibitor Sales by Country (2024-2034) & (K Units)
Table 107. Merck Company Information
Table 108. Merck Description and Major Businesses
Table 109. Merck PD-1 and PD-L1 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 110. Merck PD-1 and PD-L1 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 111. Merck Recent Developments
Table 112. Bristol-Myers Squibb Company Information
Table 113. Bristol-Myers Squibb Description and Major Businesses
Table 114. Bristol-Myers Squibb PD-1 and PD-L1 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 115. Bristol-Myers Squibb PD-1 and PD-L1 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. Bristol-Myers Squibb Recent Developments
Table 117. Pfizer Company Information
Table 118. Pfizer Description and Major Businesses
Table 119. Pfizer PD-1 and PD-L1 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 120. Pfizer PD-1 and PD-L1 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. Pfizer Recent Developments
Table 122. Sanofi Company Information
Table 123. Sanofi Description and Major Businesses
Table 124. Sanofi PD-1 and PD-L1 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 125. Sanofi PD-1 and PD-L1 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. Sanofi Recent Developments
Table 127. Regeneron Pharmaceuticals Company Information
Table 128. Regeneron Pharmaceuticals Description and Major Businesses
Table 129. Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 130. Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. Regeneron Pharmaceuticals Recent Developments
Table 132. Roche Company Information
Table 133. Roche Description and Major Businesses
Table 134. Roche PD-1 and PD-L1 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 135. Roche PD-1 and PD-L1 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. Roche Recent Developments
Table 137. AstraZeneca Company Information
Table 138. AstraZeneca Description and Major Businesses
Table 139. AstraZeneca PD-1 and PD-L1 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 140. AstraZeneca PD-1 and PD-L1 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 141. AstraZeneca Recent Developments
Table 142. Bristol Myers Squibb Company Information
Table 143. Bristol Myers Squibb Description and Major Businesses
Table 144. Bristol Myers Squibb PD-1 and PD-L1 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 145. Bristol Myers Squibb PD-1 and PD-L1 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 146. Bristol Myers Squibb Recent Developments
Table 147. Hengrui Medicine Company Information
Table 148. Hengrui Medicine Description and Major Businesses
Table 149. Hengrui Medicine PD-1 and PD-L1 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 150. Hengrui Medicine PD-1 and PD-L1 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 151. Hengrui Medicine Recent Developments
Table 152. Beigene Company Information
Table 153. Beigene Description and Major Businesses
Table 154. Beigene PD-1 and PD-L1 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 155. Beigene PD-1 and PD-L1 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 156. Beigene Recent Developments
Table 157. Innovent Biologics Company Information
Table 158. Innovent Biologics Description and Major Businesses
Table 159. Innovent Biologics PD-1 and PD-L1 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 160. Innovent Biologics PD-1 and PD-L1 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 161. Innovent Biologics Recent Developments
Table 162. Junshi Biosciences Company Information
Table 163. Junshi Biosciences Description and Major Businesses
Table 164. Junshi Biosciences PD-1 and PD-L1 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 165. Junshi Biosciences PD-1 and PD-L1 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 166. Junshi Biosciences Recent Developments
Table 167. Akeso Company Information
Table 168. Akeso Description and Major Businesses
Table 169. Akeso PD-1 and PD-L1 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 170. Akeso PD-1 and PD-L1 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 171. Akeso Recent Developments
Table 172. Alphamab Oncology Company Information
Table 173. Alphamab Oncology Description and Major Businesses
Table 174. Alphamab Oncology PD-1 and PD-L1 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 175. Alphamab Oncology PD-1 and PD-L1 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 176. Alphamab Oncology Recent Developments
Table 177. Key Raw Materials Lists
Table 178. Raw Materials Key Suppliers Lists
Table 179. PD-1 and PD-L1 Inhibitor Distributors List
Table 180. PD-1 and PD-L1 Inhibitor Customers List
Table 181. PD-1 and PD-L1 Inhibitor Market Trends
Table 182. PD-1 and PD-L1 Inhibitor Market Drivers
Table 183. PD-1 and PD-L1 Inhibitor Market Challenges
Table 184. PD-1 and PD-L1 Inhibitor Market Restraints
Table 185. Research Programs/Design for This Report
Table 186. Key Data Information from Secondary Sources
Table 187. Key Data Information from Primary Sources
List of Figures
Figure 1. PD-1 and PD-L1 Inhibitor Product Picture
Figure 2. Global PD-1 and PD-L1 Inhibitor Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global PD-1 and PD-L1 Inhibitor Market Share by Type in 2022 & 2034
Figure 4. Monoclonal Antibody Product Picture
Figure 5. Bispecific Antibody Product Picture
Figure 6. Global PD-1 and PD-L1 Inhibitor Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 7. Global PD-1 and PD-L1 Inhibitor Market Share by Application in 2022 & 2034
Figure 8. Lung Cancer
Figure 9. Stomach Cancer
Figure 10. Breast Cancer
Figure 11. Rectal Cancer
Figure 12. Others
Figure 13. PD-1 and PD-L1 Inhibitor Report Years Considered
Figure 14. Global PD-1 and PD-L1 Inhibitor Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 15. Global PD-1 and PD-L1 Inhibitor Revenue 2018-2034 (US$ Million)
Figure 16. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 17. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Region (2018-2034)
Figure 18. Global PD-1 and PD-L1 Inhibitor Sales 2018-2034 ((K Units)
Figure 19. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Region (2018-2034)
Figure 20. US & Canada PD-1 and PD-L1 Inhibitor Sales YoY (2018-2034) & (K Units)
Figure 21. US & Canada PD-1 and PD-L1 Inhibitor Revenue YoY (2018-2034) & (US$ Million)
Figure 22. Europe PD-1 and PD-L1 Inhibitor Sales YoY (2018-2034) & (K Units)
Figure 23. Europe PD-1 and PD-L1 Inhibitor Revenue YoY (2018-2034) & (US$ Million)
Figure 24. China PD-1 and PD-L1 Inhibitor Sales YoY (2018-2034) & (K Units)
Figure 25. China PD-1 and PD-L1 Inhibitor Revenue YoY (2018-2034) & (US$ Million)
Figure 26. Asia (excluding China) PD-1 and PD-L1 Inhibitor Sales YoY (2018-2034) & (K Units)
Figure 27. Asia (excluding China) PD-1 and PD-L1 Inhibitor Revenue YoY (2018-2034) & (US$ Million)
Figure 28. Middle East, Africa and Latin America PD-1 and PD-L1 Inhibitor Sales YoY (2018-2034) & (K Units)
Figure 29. Middle East, Africa and Latin America PD-1 and PD-L1 Inhibitor Revenue YoY (2018-2034) & (US$ Million)
Figure 30. The PD-1 and PD-L1 Inhibitor Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 31. The Top 5 and 10 Largest Manufacturers of PD-1 and PD-L1 Inhibitor in the World: Market Share by PD-1 and PD-L1 Inhibitor Revenue in 2022
Figure 32. Global PD-1 and PD-L1 Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 33. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Type (2018-2034)
Figure 34. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Type (2018-2034)
Figure 35. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Application (2018-2034)
Figure 36. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Application (2018-2034)
Figure 37. US & Canada PD-1 and PD-L1 Inhibitor Sales Market Share by Type (2018-2034)
Figure 38. US & Canada PD-1 and PD-L1 Inhibitor Revenue Market Share by Type (2018-2034)
Figure 39. US & Canada PD-1 and PD-L1 Inhibitor Sales Market Share by Application (2018-2034)
Figure 40. US & Canada PD-1 and PD-L1 Inhibitor Revenue Market Share by Application (2018-2034)
Figure 41. US & Canada PD-1 and PD-L1 Inhibitor Revenue Share by Country (2018-2034)
Figure 42. US & Canada PD-1 and PD-L1 Inhibitor Sales Share by Country (2018-2034)
Figure 43. U.S. PD-1 and PD-L1 Inhibitor Revenue (2018-2034) & (US$ Million)
Figure 44. Canada PD-1 and PD-L1 Inhibitor Revenue (2018-2034) & (US$ Million)
Figure 45. Europe PD-1 and PD-L1 Inhibitor Sales Market Share by Type (2018-2034)
Figure 46. Europe PD-1 and PD-L1 Inhibitor Revenue Market Share by Type (2018-2034)
Figure 47. Europe PD-1 and PD-L1 Inhibitor Sales Market Share by Application (2018-2034)
Figure 48. Europe PD-1 and PD-L1 Inhibitor Revenue Market Share by Application (2018-2034)
Figure 49. Europe PD-1 and PD-L1 Inhibitor Revenue Share by Country (2018-2034)
Figure 50. Europe PD-1 and PD-L1 Inhibitor Sales Share by Country (2018-2034)
Figure 51. Germany PD-1 and PD-L1 Inhibitor Revenue (2018-2034) & (US$ Million)
Figure 52. France PD-1 and PD-L1 Inhibitor Revenue (2018-2034) & (US$ Million)
Figure 53. U.K. PD-1 and PD-L1 Inhibitor Revenue (2018-2034) & (US$ Million)
Figure 54. Italy PD-1 and PD-L1 Inhibitor Revenue (2018-2034) & (US$ Million)
Figure 55. Russia PD-1 and PD-L1 Inhibitor Revenue (2018-2034) & (US$ Million)
Figure 56. China PD-1 and PD-L1 Inhibitor Sales Market Share by Type (2018-2034)
Figure 57. China PD-1 and PD-L1 Inhibitor Revenue Market Share by Type (2018-2034)
Figure 58. China PD-1 and PD-L1 Inhibitor Sales Market Share by Application (2018-2034)
Figure 59. China PD-1 and PD-L1 Inhibitor Revenue Market Share by Application (2018-2034)
Figure 60. Asia PD-1 and PD-L1 Inhibitor Sales Market Share by Type (2018-2034)
Figure 61. Asia PD-1 and PD-L1 Inhibitor Revenue Market Share by Type (2018-2034)
Figure 62. Asia PD-1 and PD-L1 Inhibitor Sales Market Share by Application (2018-2034)
Figure 63. Asia PD-1 and PD-L1 Inhibitor Revenue Market Share by Application (2018-2034)
Figure 64. Asia PD-1 and PD-L1 Inhibitor Revenue Share by Region (2018-2034)
Figure 65. Asia PD-1 and PD-L1 Inhibitor Sales Share by Region (2018-2034)
Figure 66. Japan PD-1 and PD-L1 Inhibitor Revenue (2018-2034) & (US$ Million)
Figure 67. South Korea PD-1 and PD-L1 Inhibitor Revenue (2018-2034) & (US$ Million)
Figure 68. China Taiwan PD-1 and PD-L1 Inhibitor Revenue (2018-2034) & (US$ Million)
Figure 69. Southeast Asia PD-1 and PD-L1 Inhibitor Revenue (2018-2034) & (US$ Million)
Figure 70. India PD-1 and PD-L1 Inhibitor Revenue (2018-2034) & (US$ Million)
Figure 71. Middle East, Africa and Latin America PD-1 and PD-L1 Inhibitor Sales Market Share by Type (2018-2034)
Figure 72. Middle East, Africa and Latin America PD-1 and PD-L1 Inhibitor Revenue Market Share by Type (2018-2034)
Figure 73. Middle East, Africa and Latin America PD-1 and PD-L1 Inhibitor Sales Market Share by Application (2018-2034)
Figure 74. Middle East, Africa and Latin America PD-1 and PD-L1 Inhibitor Revenue Market Share by Application (2018-2034)
Figure 75. Middle East, Africa and Latin America PD-1 and PD-L1 Inhibitor Revenue Share by Country (2018-2034)
Figure 76. Middle East, Africa and Latin America PD-1 and PD-L1 Inhibitor Sales Share by Country (2018-2034)
Figure 77. Brazil PD-1 and PD-L1 Inhibitor Revenue (2018-2034) & (US$ Million)
Figure 78. Mexico PD-1 and PD-L1 Inhibitor Revenue (2018-2034) & (US$ Million)
Figure 79. Turkey PD-1 and PD-L1 Inhibitor Revenue (2018-2034) & (US$ Million)
Figure 80. Israel PD-1 and PD-L1 Inhibitor Revenue (2018-2034) & (US$ Million)
Figure 81. GCC Countries PD-1 and PD-L1 Inhibitor Revenue (2018-2034) & (US$ Million)
Figure 82. PD-1 and PD-L1 Inhibitor Value Chain
Figure 83. PD-1 and PD-L1 Inhibitor Production Process
Figure 84. Channels of Distribution
Figure 85. Distributors Profiles
Figure 86. Bottom-up and Top-down Approaches for This Report
Figure 87. Data Triangulation
Figure 88. Key Executives Interviewed